133 318

Cited 20 times in

Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.

Authors
Jeong, SH; Lee, HW; Han, JH; Kang, SY; Choi, JH; Jung, YM; Choi, H; Oh, YT; Park, KJ; Hwang, SC; Sheen, SS; Oh, YJ; Kim, JH; Lim, HY
Citation
Japanese journal of clinical oncology, 38(10):661-669, 2008
Journal Title
Japanese journal of clinical oncology
ISSN
0368-28111465-3621
Abstract
OBJECTIVE: The present study evaluated the prognostic significance of apoptosis-related proteins p53, Bax and galectin-3 in patients with non-small cell lung cancer (NSCLC) treated with surgical resection. METHODS: We investigated the expression of these proteins and their association with clinicopathologic characteristics including disease-free survival (DFS) and overall survival (OS) in 205 NSCLC patients who underwent surgical resection (Stage I, 97; II, 46; IIIA, 45; IIIB, 17) using immunohistochemistry. Eighty-eight patients (43%) received adjuvant treatment (chemotherapy: 8, radiotherapy: 24, both: 56). RESULTS: High expressions of Bax, p53 and galectin-3 were observed in 48 (23%), 81 (40%) and 105 (51%) patients, respectively. Low expression of Bax was significantly associated with male gender, squamous cell histology and low expression of galectin-3. Five-year DFS and OS of total patients were 37 and 46%, respectively. High expressions of p53 and galectin-3 were not associated with poor DFS or OS, and no significant correlation existed between low expression of Bax and outcome of patients. However, in patients with non-squamous histology (108 patients), low expression of Bax was a significant independent predictor of poor DFS (P = 0.017) and OS (P = 0.037). In addition, in patients with Stage II or III disease, low expression of Bax significantly correlated with poor DFS (P = 0.004). It was also the most significant independent poor prognostic factor second only to a large primary tumor size in Stage II or III patients with non-squamous histology. CONCLUSIONS: Low expression of Bax was significantly associated with poor prognosis in resected NSCLC patients with non-squamous histology.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarboplatin/administration & dosageCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/metabolism*Carcinoma, Non-Small-Cell Lung/secondaryCarcinoma, Squamous Cell/drug therapyCarcinoma, Squamous Cell/metabolism*Carcinoma, Squamous Cell/secondaryChemotherapy, AdjuvantCombined Modality TherapyDeoxycytidine/administration & dosageDeoxycytidine/analogs & derivativesFemaleGalectin 3/metabolismHumansImmunoenzyme TechniquesLung Neoplasms/drug therapyLung Neoplasms/metabolism*Lung Neoplasms/pathologyMaleMiddle AgedNeoplasm StagingPrognosisRadiotherapy DosageRetrospective StudiesSurvival RateTissue Array AnalysisTumor Suppressor Protein p53/metabolismbcl-2-Associated X Protein/metabolism*
DOI
10.1093/jjco/hyn089
PMID
18772168
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Thoracic & Cardiovascular Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
정성현이현우한재호강석윤최진혁최호오영택박광주황성철신승수김장희
Full Text Link
Files in This Item:
661-669.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse